ArticleMedicine2026
Association of antihypertensive drugs, intestinal ischemia, and breast diseases: A drug-target Mendelian Randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Both hypertensive and breast diseases impose a significant societal burden. However, the correlation between antihypertensive drug use and breast cancer remains controversial. We aimed to determine their potential correlations and explore their possible mechanisms. We performed summary data-based Mendelian Randomization (SMR) analysis of expression quantitative trait loci (eQTL) data from the blood of patients with breast diseases. We then performed drug-targeting Mendelian Randomization (MR) analysis using blood pressure-related single nucleotide polymorphism (SNPs) as instrumental variables (IVs). False discovery rate (FDR) correction was performed for reliable results, and colocalization analysis was performed to clarify shared gene variants. Mediation MR methods were used to investigate the mechanistic pathways involved in this association. Combined with the results of SMR analysis and drug-targeting MR analysis, loop diuretics aggravated overall breast cancer (OR_SMR = 0.842, 95% CI_SMR: 0.778-0.911, P_SMR_FDR = 0.008) and ER + breast cancer (OR_SMR = 0.854, 95% CI_SMR: 0.778-0.937, P_SMR_FDR = 0.008) within SLC12A2 gene loci. Colocalization analysis showed that SLC12A2-targeted drugs share a common variant site with breast cancer. Mediation analyses suggested that the pathway related to intestinal ischemia mediated 73.711% of the total effect on over breast cancer risk in the SLC12A2 gene loci. Antihypertensive drugs increase the overall risk of breast cancer and ER + breast cancer within the SLC12A2 gene. And overall breast cancer risk which may result from intestinal ischemia. Given the long-term safety of antihypertensive drugs, significance should be attached to the prevention and early detection of breast cancer in patients taking loop diuretics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.